IFNG and cancer: IFN-γ mostly elicits PD‐L1 expression in cancer cells through the IFN-γ/JAK signaling pathway; indeed, IFN-γ treatment followed by PD‐L1 blockade was shown to result in enhanced anti-cancer T-cell cytotoxicity (42).